GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Patients in the belimumab group outpaced those on standard immunotherapy as early as 3 months in meeting the primary outcome and were more likely to sustain it through 24 months (HR = 0.631; 95% ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus (SLE) when added to standard therapy, according to study results ...

Patients with non-renal SLE who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.

Belimumab is an anti-BAFF monoclonal antibody that has been approved by the FDA to treat systemic lupus erythematosus (SLE). BAFF and interleukin 6 expression have been shown to beheightened in ...

Long-term treatment with belimumab slows the key drivers of organ damage — disease activity, severe flares, and glucocorticoid exposure — in patients with systemic lupus erythematosus (SLE ...

Benlysta (belimumab) Analytical Perspective • In-depth Benlysta (belimumab) Market Assessment This report provides a detailed market assessment of Benlysta (belimumab) in Seven Major Markets, i ...

The authors said belimumab did not spark statistically significant benefits either in terms of reducing relapses (1.4 in the 6 months on therapy vs 2.0 in the 6 months before therapy; P = .21) or ...

Belimumab is a monoclonal antibody, prescribed for active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. Belimumab Interaction with 77 drugs.

Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 ...

A new study finds that belimumab (Benlysta®) is an effective therapy option for people with cutaneous lupus erythematosus (CLE), a form of lupus that affects the skin. This study highlights that ...

In older adults (ages 65+) with lupus, belimumab (Benlysta®) is a safe and effective treatment option, and is beneficial in overall populations with the disease. Belimumab was the first FDA-approved ...